Navigation Links
Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
Date:10/11/2007

Sagent to Accelerate Anesiva's Penetration of the Hospital Market with

Zingo

SOUTH SAN FRANCISCO, Calif. and SCHAUMBURG, Ill., Oct. 11 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) and Sagent Pharmaceuticals, Inc., today announced an agreement in which Sagent will co-promote for three years Anesiva's Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection product and will manage U.S. distribution. Zingo, a needle-free product that provides fast-acting topical, local analgesia, has been recently approved by the U.S. Food and Drug Administration (FDA) to reduce the pain associated with venous access procedures, such as IV insertions or blood draws, in children three to 18 years of age.

Under the agreement, Sagent will join with Anesiva to co-promote Zingo within hospitals as well as facilitating contract negotiations with hospitals and group purchasing organizations. Sagent's team will focus their selling efforts toward hospital pharmacists, with Anesiva promoting primarily to physicians and nurses. In addition, Sagent will manage Zingo warehousing and distribution services. The terms of the agreement provide for Sagent to earn a royalty based on Anesiva's net sales of Zingo and for Anesiva to reimburse Sagent for certain direct expenses. Anesiva may designate additional marketing partners to address non-hospital affiliated markets.

"We are very excited to work with their extremely seasoned sales and national accounts team to support Zingo's penetration of the hospital market," said John P. McLaughlin, chief executive officer of Anesiva. "Together with Anesiva's experienced marketing organization and planned sales force of 15 representa
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. JT Packard exec resigns after settling copyright disputes
2. Cray signs $250M deal to develop supercomputer
3. Donley resigns as WiCell director
4. WARF signs licensing pact with BD Biosciences
5. TeraMedica signs agreement with ThedaCare
6. CATI signs agreement for food processing technology
7. Doyle signs bill that impacts electronic medical records
8. Doyle signs "self-dealing" bill
9. Electronic signs for municipalities: Las Vegas or lost revenues?
10. NorthStar signs exclusive agreement with Illinois foundation
11. Renaissance Learning CEO resigns to start company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
(Date:1/14/2014)... 2014 BioMedomics, Inc. , a Point ... platforms and novel disease specific POC tests, announced today that ... a total of $690,000. The investment is from private investors ... This group of private investors has significant successful experience in ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... 26 Advanced Life Sciences Holdings, ... in the discovery, development and commercialization of novel drugs in ... announced positive results from in vitro and ... its novel oral antibiotic, against the species of Plasmodium ...
... ... be responsible for leading the MM-121 research team through Development and creating the Company’s ... ... held biotechnology company focused on the discovery and development of novel treatments for cancer ...
... MORRISTOWN, N.J. , May 25 ... confirmed that its subsidiary, Watson Laboratories, Inc. filed an ... and Drug Administration (FDA) seeking approval to market sevelamer ... generic version of Genzyme,s Renvela®.  Renvela ® is a ...
Cached Biology Technology:Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 2Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 5Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research 2Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research 3Watson Confirms Renvela® Patent Challenge 2Watson Confirms Renvela® Patent Challenge 3
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
(Date:4/18/2014)... as soon as they,re planted may be good news for ... In the wild, a plant whose seeds sprouted at the ... than just an insurance policy against late frosts or unexpected ... advantages too: Plants whose seeds put off sprouting until ... in a team of researchers working at the National Evolutionary ...
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis ... drugs that act against various bacteria, fungal infections and ... University of Illinois chemists and collaborators. , Led by ... determined the different ways the drug SQ109 attacks the ... target other pathogens from yeast to malaria and ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2Multitarget TB drug could treat other diseases, evade resistance 2
... in German . , The detector ... has a very low error rate. The results have ... Ultrafast, efficient, and reliable single-photon detectors are among the ... have not yet reached maturity for practical application. Physicist ...
... Caroline Leck of Stockholm University has evaluated the Norwegian ... sensational," says Dr Leck. "If confirmed by other studies, ... the political targets for climate." Temperature rise ... temperature climbed sharply through the 1990s, the increase has ...
... Daubenton,s bat, the attractions of family life seem to vary ... sex. For more than a decade, a team led ... of Biology has studied a population of several hundred bats ... roosts in Ilkley and Addingham, upstream in the market town ...
Cached Biology News:Quantum communication: Each photon counts 2Global warming less extreme than feared? 2Global warming less extreme than feared? 3Global warming less extreme than feared? 4Bats split on family living 2Bats split on family living 3
... of glass plates, bar clamp, and a ... of these units are:, safety interlock lids ... , upper and lower reservoirs have drains ... disposal of buffer solutions , leveling base ...
Contact us for more information...
Mol wt: average mol wt16,951.27 Da by calculation...
... The FailSafe™ PCR System is the ... the first time and every time. It ... regardless of the source or the property ... EPICENTRE's FailSafe™ PCR Enzyme Mix, a unique ...
Biology Products: